Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.65 SEK | +0.58% | +0.58% | +32.67% |
06-18 | Lipum AB Completes Multiple Dose Part of the Phase I Clinical Study | CI |
05-28 | Lipum AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
Fiscal Period: December | 2021 | 2023 | 2024 | 2025 |
---|---|---|---|---|
Capitalization 1 | 93.47 | 182.4 | 182.4 | - |
Enterprise Value (EV) 1 | 93.47 | 60.73 | 128.1 | 182.4 |
P/E ratio | -1.48 x | - | - | - |
Yield | - | - | - | - |
Capitalization / Revenue | - | - | - | - |
EV / Revenue | - | - | - | - |
EV / EBITDA | - | -1.63 x | -4.45 x | -3.97 x |
EV / FCF | - | - | -4,800,708 x | -3,965,804 x |
FCF Yield | - | - | -0% | -0% |
Price to Book | - | - | - | - |
Nbr of stocks (in thousands) | 5,052 | 21,212 | 21,212 | - |
Reference price 2 | 18.50 | 8.600 | 8.600 | 8.600 |
Announcement Date | 3/25/22 | 2/29/24 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|
Net sales | - | - | - | - | - |
EBITDA 1 | - | - | -37.21 | -41 | -46 |
EBIT 1 | - | -37.92 | -37.25 | -41 | -46 |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | - | -37.18 | -41 | -46 |
Net income 1 | -52.26 | -38.08 | -37.18 | -41 | -46 |
Net margin | - | - | - | - | - |
EPS | -12.54 | - | - | - | - |
Free Cash Flow | - | - | - | -38 | -46 |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 3/25/22 | 3/24/23 | 2/29/24 | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|
Net Debt | - | - | - | - | - |
Net Cash position | - | - | - | 54.3 | - |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow | - | - | - | -38 | -46 |
ROE (net income / shareholders' equity) | - | - | - | -1,720% | -1,859% |
ROA (Net income/ Total Assets) | - | - | - | - | - |
Assets 1 | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - |
Capex | - | - | - | - | - |
Capex / Sales | - | - | - | - | - |
Announcement Date | 3/25/22 | 3/24/23 | 2/29/24 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+32.67% | 17.34M | |
+2.87% | 94.22B | |
-4.08% | 37.76B | |
-13.80% | 32.5B | |
+73.38% | 27.75B | |
-11.65% | 16.13B | |
-0.67% | 14.19B | |
-11.67% | 11.42B | |
+190.36% | 11.06B | |
-52.61% | 9.09B |
- Stock Market
- Equities
- LIPUM Stock
- Financials Lipum AB